First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.18 CNY 2.81% Market Closed
Updated: Apr 25, 2024
Section:
 

Intrinsic Value

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. [ Read More ]

The intrinsic value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 21.08 CNY. Compared to the current market price of 13.18 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 37%.

Key Points:
Intrinsic Value
Base Case
21.08 CNY
Undervaluation 37%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case
What is intrinsic value?

Valuation Backtest
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Nanjing King-friend Biochemical Pharmaceutical Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

What unique competitive advantages
does Nanjing King-friend Biochemical Pharmaceutical Co Ltd hold over its rivals?

What risks and challenges
does Nanjing King-friend Biochemical Pharmaceutical Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide an overview of the primary business activities
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

What unique competitive advantages
does Nanjing King-friend Biochemical Pharmaceutical Co Ltd hold over its rivals?

What risks and challenges
does Nanjing King-friend Biochemical Pharmaceutical Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide P/S
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide P/E
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide P/OCF
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide P/FCFE
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide P/B
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/S
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/GP
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/EBITDA
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/EBIT
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/OCF
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/FCFF
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide EV/IC
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Show me price targets
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd made by professional analysts.

What are the Revenue projections
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

How accurate were the past Revenue estimates
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

What are the Net Income projections
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

How accurate were the past Net Income estimates
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

What are the EPS projections
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

How accurate were the past EPS estimates
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

What are the EBIT projections
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

How accurate were the past EBIT estimates
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

Compare the revenue forecasts
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nanjing King-friend Biochemical Pharmaceutical Co Ltd compared to its peers.

Compare the P/E ratios
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Nanjing King-friend Biochemical Pharmaceutical Co Ltd with its peers.

Analyze the financial leverage
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd compared to its main competitors.

Show all profitability ratios
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide ROE
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide ROA
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide ROIC
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide ROCE
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Gross Margin
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Operating Margin
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Net Margin
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide FCF Margin
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Show all solvency ratios
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide D/E Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide D/A Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Interest Coverage Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Altman Z-Score Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Quick Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Current Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Provide Cash Ratio
for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

What is the historical Revenue growth
over the last 5 years for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

What is the historical Net Income growth
over the last 5 years for Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

What is the current Free Cash Flow
of Nanjing King-friend Biochemical Pharmaceutical Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nanjing King-friend Biochemical Pharmaceutical Co Ltd.

Popular Strategic Analysis Valuation Future Outlook Peer Analysis Profitability Solvency Financials
Financials
Revenue
Operating Income
Net Income
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Balance Sheet Decomposition
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

11.1B
Assets
4.3B
Liabilities
11.1B
Assets
4.3B
Liabilities
Current Assets 9.3B
Cash & Short-Term Investments 4.5B
Receivables 1.2B
Other Current Assets 3.5B
Non-Current Assets 1.9B
Long-Term Investments 68.4m
PP&E 1.2B
Intangibles 446.7m
Other Non-Current Assets 138.1m
Current Liabilities 3.7B
Accounts Payable 610.9m
Accrued Liabilities 78.7m
Short-Term Debt 2.3B
Other Current Liabilities 710.2m
Non-Current Liabilities 638m
Long-Term Debt 516.8m
Other Non-Current Liabilities 121.2m
Efficiency

Earnings Waterfall
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Revenue
4B CNY
Cost of Revenue
-2B CNY
Gross Profit
2B CNY
Operating Expenses
-904.7m CNY
Operating Income
1.1B CNY
Other Expenses
-34.2m CNY
Net Income
1B CNY
Gross Margin
Operating Margin
Net Margin
FCF Margin
ROE
ROA
ROIC
ROCE

Free Cash Flow Analysis
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

Profitability Score
Profitability Due Diligence

Nanjing King-friend Biochemical Pharmaceutical Co Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROE
Positive Net Income
61/100
Profitability
Score

Nanjing King-friend Biochemical Pharmaceutical Co Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Nanjing King-friend Biochemical Pharmaceutical Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
71/100
Solvency
Score

Nanjing King-friend Biochemical Pharmaceutical Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Wall Street analysts forecast Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Nanjing King-friend Biochemical Pharmaceutical Co Ltd is 20.59 CNY with a low forecast of 17.17 CNY and a high forecast of 24.54 CNY.

Lowest Forecast
Wall Street Target
17.17 CNY
30% Upside
Average Forecast
Wall Street Target
20.59 CNY
56% Upside
Highest Forecast
Wall Street Target
24.54 CNY
86% Upside
Lowest
Price Target
17.17 CNY
30% Upside
Average
Price Target
20.59 CNY
56% Upside
Highest
Price Target
24.54 CNY
86% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

1M 1M
+15%
6M 6M
+11%
1Y 1Y
-8%
3Y 3Y
-45%
5Y 5Y
+15%
10Y 10Y
+386%
Annual Price Range
13.18
52w Low
11.07
52w High
16.24
Price Metrics
Average Annual Return 20.32%
Standard Deviation of Annual Returns 47.85%
Max Drawdown -67%
Shares Statistics
Market Capitalization 21.3B CNY
Shares Outstanding 1 614 629 900
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

21.3B CNY

Dividend Yield

0.9%

Description

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 1,006 full-time employees. The company went IPO on 2017-07-19. The firm's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The firm mainly exports its products to the United States and European countries.

Contact

JIANGSU
Nanjing
No. 16 Xuefu Road, High-tech Industrial Development Zone
+862586990789
http://www.nkf-pharma.com

IPO

2017-07-19

Employees

1 006

Officers

Chairman & GM
Mr. Tang Yongqun
Financial Manager
Ms. Xiaojie Qian
Deputy GM, Secretary & Director
Mr. Huang Xiwei
Deputy General Manager
Ms. Wu Guiping

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is the Intrinsic Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock?

The intrinsic value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 21.08 CNY.

Is Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 13.18 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 37%.

ALPHA SPREAD
Join more than 131,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.